A Multi-center, Randomized, Double-blind, Placebo-controlled, 24 Months Study in Patients With Amnestic Mild Cognitive Impairment or Very Mild Alzheimer's Disease to Investigate the Safety, Tolerability and Immune Response of Repeated Subcutaneous Injections of ABvac40

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, 24 Months Study in Patients With Amnestic Mild Cognitive Impairment or Very Mild Alzheimer's Disease to Investigate the Safety, Tolerability and Immune Response of Repeated Subcutaneous Injections of ABvac40

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs ABvac 40 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Araclon Biotech
  • Most Recent Events

    • 08 Mar 2018 Status changed from planning to recruiting.
    • 25 Jan 2018 According to an Araclon Biotech media release, the company has decided to continue the partnership with TFS International (TFS) for this trial.
    • 27 Jun 2017 According to an Araclon Biotech media release, the company has received approval from the Spanish Agency of Medicinal Products and Medical Devices to begin phase II clinical trials for ABvac40. The company expects to initiate recruitment process in July in some of the selected facilities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top